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Carbamylated hemoglobin and carbamylated plasma protein in hemo-
dialyzed patients. The carbamylation reaction in vivo involves the nonen-
zymatic, covalent attachment of isocyanic acid, the spontaneous dissocia-
tion product of urea, to proteins. Carbamylated proteins have been
proposed as markers of uremia and indicators of uremic control. However,
the utility of measuring carbamylated proteins has not been investigated
adequately. Therefore, this study was done to determine the relationship
between the carbamylation of long-lived protein (hemoglobin) with that of
short-lived proteins (plasma proteins) in hemodialyzed patients. Signifi-
cantly higher carbamylated hemoglobin (CHb; 157 6 40 mg valine
hydantoin/g Hb) and carbamylated protein (CTP; 0.117 6 0.011 absor-
bance/mg protein) concentrations were found in hemodialyzed patients
(N 5 13) as compared to normal individuals (N 5 9, 53 6 20 mg valine
hydantoin/g Hb and 0.08 6 0.01 absorbance/mg protein, respectively). A
high correlation was found between CHb and CTP concentrations (r 5
0.87, P , 0.0001), demonstrating a strong relationship between these two
different half-lived proteins. A six-month longitudinal study of seven
hemodialyzed patients showed that the between subject correlations were
significant for CHb versus CTP as well as CHb versus pre-dialysis urea.
Correlations were not significant for CTP versus pre-dialysis urea or Kt/V,
nor CHb versus Kt/V. Carbamylated hemoglobin fluctuated the most over
this time period (30.1% 6 20.2%), pre-dialysis urea and CTP varied less
(18.3% 6 13.4% and 14.9% 6 7.5%, respectively), and Kt/V varied the
least (6.3% 6 3.3%). Within subject correlations were not significant
between any two tests. It is unclear whether the lack of correlations found
is real or a function of the small sample size. However, these data do show
that CHb and CTP are positively associated and reflect the degree of urea
exposure in the blood, but their usefulness for patients on maintenance
hemodialysis is not clear.
Increases in blood urea levels have always been associated with
a loss of kidney function. Recently, a new approach has been
taken for its measurement that has broadened the scope of its use.
Urea decomposes to give cyanate and ammonium ions [1].
Cyanate, in its unprotonated form, reacts with unpaired electrons
through a nucleophilic reaction [2, 3]. In vivo, the most stable
reactions are with the electrons of the free amino groups (a and
e), and sulfhydryl groups. Carbamylation studies done in vitro [4,
5] have demonstrated that carbamylation causes changes in
conformation, decreased or inhibition of enzyme activity, binding
changes (to receptors and drugs), and physically causes an in-
crease in anodicity on various types of proteins.
Elevated urea levels therefore not only indicate a loss of kidney
function, but may also serve as a source for potential pathophys-
iological consequences. Several reports have inferred the associ-
ation of carbamylation with symptom or loss of function such as
cataracts [6], neuropathies [7], nausea, drowsiness, memory loss
[4, 8], atherosclerosis [9, 10], and drug binding defects [12–14]. In
fact, the presence of carbamylated amino acids [15], membranes
[16, 17], lipoproteins [9], plasma proteins [12, 14, 18–20], and
hemoglobin [11, 21–27] have been found in patients with renal
failure. However, no study has yet shown by direct measurement
that symptoms seen in patients with uremia are a result of
carbamylation.
Nonetheless, there has been ample progress in assessing car-
bamylated proteins as markers of uremia [3, 11, 15, 16, 18, 19,
21–31]. This concept is analogous to that of glycated proteins in
diabetes [32]. When glucose (or cyanate or other potential
compound) makes a stable attachment to a protein, it takes on the
half-life of that protein. In the assessment of diabetics, it is these
glucose-protein adducts that reveal the past dynamics of blood
glucose levels, a time-integrated marker. Glucose or urea mea-
surements alone are subject to day-to-day dietary and metabolic
influences, thereby reflecting transient time periods. The most
common marker proteins measured are hemoglobin, which is a
long-term indicator (2 months), and albumin or total plasma
protein, which are short-term indicators (2 to 3 weeks) [33].
Carbamylated hemoglobin has been the major carbamylated
protein studied owing to initial studies that sought to use cyanate
as a therapy for sickle cell anemia [34]. Flu¨ckiger et al were the
first to identify carbamylated hemoglobin in uremic patients and
furthermore correlated HbA1 with time-averaged urea concentra-
tion [28]. Oimomi et al [29] then investigated the possibility of
using HbA1 as an indicator of control in patients with renal
failure. A time-course relationship between urea and HbA1
demonstrated a correlation with HbA1 and urea concentrations
measured one to two weeks earlier. In another study, CHb in
renal transplant patients reflected the degree of uremia two to
three weeks earlier [27].
Evaluation of carbamylated hemoglobin in patients with various
degrees of renal function has shown that its measurement has
potential clinical value (Table 1) [11, 21–27, 31]. There are
significant differences between CHb in control groups [22, 24, 31]
compared to patients with chronic renal failure [21, 22, 24, 29, 31],
patients on continuous ambulatory dialysis [22, 24], hemodialysis
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[22, 24, 28, 31], and patients with failed transplants [22]. No
differences are seen between CHb in control groups and patients
with primary renal disease [22], successful transplants [22, 24], or
diabetic patients without renal failure [21, 24, 29]. However, CHb
has been found to be capable of differentiating acute from chronic
renal impairment [25]. The positive predictive value for this test
was 80% with a sensitivity of 100% when the ratio of CHb/
creatinine was set at 0.2.
Furthermore, there are significant correlations between car-
bamylated hemoglobin values compared to urea, creatinine, and
time-averaged urea concentration (TAC) measurements [11, 21–
24, 27–29], but not with bicarbonate and phosphate values [31].
Considerably less information is available on the relationship of
other carbamylated compounds in renal patients. However, car-
bamylated plasma protein (CTP) [12, 14, 18, 19], leukocytes [16],
erythrocytes, and amino acids [15] in uremic individuals have all
been found to be higher compared to normal individuals. Table 2
lists the carbamylated protein values in normal individuals and
patients with renal failure who have been reported in the litera-
ture.
Measurement of carbamylated protein could therefore provide
the clinical information needed as an indicator of uremic control.
It could be used to monitor the deterioration of renal function, to
assess compliance to dietary therapy, and to evaluate the ade-
quacy of dialysis treatment [23]. The benefit of using carbamylated
proteins as markers is that they can be used as alternatives to TAC
measurements, particularly in dialyzed patients. The currently
accepted method to quantify dialysis therapy and define its
adequacy is through a mathematical description of urea balance
called urea kinetic modeling (UKM) [39]. The calculation of
UKM parameters requires collection of numerous pieces of data,
including accurately timed urea measurements, and a computer to
solve the simultaneous equations. In comparison, measurement of
carbamylated protein requires only a single measurement on one
blood sample that could be performed easily in a clinical labora-
tory.
However, more clinical studies are needed to fully establish the
usefulness of carbamylated protein measurement in dialyzed
patients, particularly in assessing adequacy of dialysis. Therefore,
a six-month longitudinal study was undertaken to evaluate the
changes in carbamylated hemoglobin, carbamylated protein, urea,
and dialysis dose (Kt/V, a UKM derived parameter) in seven
thrice weekly hemodialyzed patients. Furthermore, the relation-
ship between CTP and CHb concentrations in normal individuals
and hemodialyzed patients were assessed.
METHODS
Chemicals
N-Carbamyl-DL-valine (CVAL), N-carbamyl-DL-norvaline
(CNVal), albumin (;99%), and 4-aminodiphenylamine (semi-
dine) were purchased from Sigma Chemical Co. (St. Louis, MO,
Table 1. Carbamylated hemoglobin (CHb) values in normal individuals
and patients with renal failure
CHba
mg CVAL/g Hb
Patients
N Reference
Normal
Normal renal function 25 (2) 27 [35]
34 (20–63) 31 [36]
26 (2) 20 [22]
28 (n/a) 20 [25]
41 (12) 25 [21]
37 (7) (n/a) [27]
37 (7) 30 [24]
96 (24) 13 [37]
38 (12) 33 [24]
Diabetic
IDDM 38 (11) 24 [21]
IDDM and NIDDM 38 (11) 29 [24]
Primary renal disease 29 (2) 22 [22]
Nonsymptomatic
Prerenal azotemia 166 (88) 16 [37]
Renal failure
Acute renal failure
,10 day 29 (27–35) 11 [25]
33.7 (24.6–55.8) b [36]
.10 days 72 (60–83) 9 [25]
68.7 (36.0–93.9) b [36]
Acute on chronic renal
failure
42 (31–67) 22 [24]
Chronic renal failure 137 (10) 40 [22]
164 (88) 30 [21]
186 (92) 43 [24]
148 (122–210) 24 [24]
115 (34.6–286.5) 53 [36]
Continuous ambulatory
peritoneal dialysis
127 (8) 24 [22]
143 (32) 18 [24]
Hemodialysis
100 (5) 31 [22]
131 (42) 27 [24]
106.5 (38.2) 55 [35]
Adequate dialysis,
adequate PNc
142 (29) 11 [23]
Inadequate dialysis,
adequate PN
197 (30) 6 [23]
Adequate dialysis,
inadequate PN
105 (28) 3 [23]
Transplant
43 (4) 16 [22]
76 (33) 16 [24]
Transplant (renal
failure)
87 (14) 14 [22]
a Data are mean 6 SEM [22], median and interquartile ranges [25],
median and range [36], mean 6 standard deviation [21, 23, 24, 27, 35, 37]
b ,10 days and .10 days 5 37 patients
c Protein nutrition
Table 2. Carbamylated protein values in normal individuals and
patients with renal failure
Protein
Normal
mg HC/g proteina
Uremic
mg HC/g protein Reference
Total protein
Carbamyl
groups
ND 1247 (284) [12]
Homocitrullinea ;208 ;473 [19]
Albumin
Carbamyl
groups
ND 938 (378) [38]
Homocitrullineb 219 (164–329) 737 (55–903) [14]
For comparison purposes carbamyl groups were assumed to be homo-
citrulline residues.
Conversion factors used were 69,000 g/mol for HSA and 189 g/mol for
homocitrulline.
Values in parentheses are SD’s or ranges. ND is not detected.
* mg homocitrulline/g protein.
a Estimated from a graph
b Calculated from molar ratio’s.
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USA). High pressure liquid chromotomographic (HPLC) grade
acetonitrile and acetic acid, diacetyl monoxime, and sulphuric acid
were purchased from BDH Inc. (Toronto, ON, Canada). 2-Ami-
nobenzoic acid was from Aldrich Chemical Co. Inc. (Milwaukee,
WI, USA).
Patients
Seven stable outpatient hemodialyzed patients who were dia-
lyzed thrice weekly in the Renal Dialysis Unit at the Hotel
Dieu-Grace Hospitals (Grace site) were evaluated in the longitu-
dinal study (selection based on availability of blood samples for six
consecutive months). All patients had been on maintenance
hemodialysis for more than one year and had not received any
blood transfusions, nor were they on erythropoetin during the
course of the study. Approval for the study was given by both the
University of Windsor Ethics Committee and the Salvation Army
Grace Hospital (now Hotel Dieu-Grace Hospitals), Windsor,
Ontario, Canada.
For the cross-sectional study, a random selection of hemodia-
lyzed patients (N 5 13) and outpatients (N 5 9) with normal urea
and glucose, were chosen for the uremic group and normal group,
respectively.
Blood samples
Ethylenediaminetetraacetic acid (EDTA) whole blood and
serum were drawn during regular dialysis treatments and the
routine tests performed on them. The whole blood samples were
further processed for determination of CHb and CTP. These
samples were stored overnight at 4°C routinely and up to two
weeks in some cases. Although carbamylation does not cease at
low temperatures [40], no significant changes in CHb values were
found during this time period. This is in agreement with Kwan et
al [21] and reflective of in vitro urea decomposition studies [41].
Only slight hemolysis (1 to 2%) was seen in a few samples. Red
cells were separated from the plasma by centrifugation, washed
three times with phosphate buffered saline (PBS) and resus-
pended in an equal volume of PBS. The plasma and the washed
red blood cells were then used immediately or frozen at 220°C
until required.
Measurements
Blood tests. Serum samples were analyzed for urea, creatinine,
phosphate, total protein (TP), albumin, calcium (total and ion-
ized), potassium, sodium, chloride, carbon dioxide, glucose, alka-
line phosphatase, g-glutamyl transferase, and aspartate amino-
transferase (Ektachem 700 or 700XR; Eastman Kodak Co.,
Rochester, NY, USA). Hemoglobin measurements were made
using a total hemoglobin test kit (Sigma Diagnostics Canada,
Mississauga, ON, Canada). Low concentrations of protein were
measured manually using the Bio-Rad Protein Assay kit (Bio-Rad
Laboratories Ltd., Mississauga, ON, Canada), with human serum
albumin as standard.
Preparation of carbamylated albumin. Human serum albumin
(99%) was carbamylated by incubation with 100 mM sodium
cyanate in 0.1 M phosphate buffer, pH 7.4 at room temperature.
The incubation time varied depending on the extent of carbamy-
lation required. Unreacted cyanate was removed from the protein
by gel filtration (Bio-Gel P-6G). The extent of carbamylation was
estimated with the trinitrobenzene-sulfonic acid assay [42]. Cy-
anate removal was detected by reaction with 2-aminobenzoic acid
[43].
Measurement of protein carbamylation. The determination of
protein carbamylation was based on the method of Hunninghake
and Grisolia [44]. Plasma samples were first passed through a
Sephadex G-25 column (1 3 8.5 cm) to remove urea and other
potential interfering small molecules. Briefly, into a 10-ml boro-
silicate test tube the following was added in order: 1 ml sample or
control (albumin or carbamylated albumin), 0.5 ml diacetylmon-
oxime (3% wt/vol), 0.5 ml H2SO4, and 0.5 ml semidine (0.2%
wt/vol). The mixture was vortexed and heated for 10 minutes at
90°C. The mixture was then allowed to cool for 5 to 10 minutes
(temperature 30° to 60°C). Then, 1 ml of a 0.001 M FeCl3-H2SO4
solution was added and mixed thoroughly. The mixture was
cooled to room temperature and absorbances read within one
hour at 525 nm. The extent of protein carbamylation was ex-
pressed in relative units (absorbance/mg protein) since no appro-
priate standard is available for this method. This assay was found
to be linear with amount of carbamylated albumin (CHSA) tested.
Carbamylated albumin (74%) was used as the positive control.
In vitro preparation of valine hydantoin. Valine hydantoin (VH)
standard was prepared by incubating carbamyl valine (13.5 mg)
with 11.6 M HCl (5 ml) for eight hours in a dri-bath set at 120°C
and then left overnight at room temperature [45]. The solution
was rotoevaporated until only a few drops of yellow liquid
remained. The tube was then left under a vacuum overnight to
remove the last traces of liquid. The resulting residue was slightly
yellowish and had a melting point of 145°C. The residue was
redissolved in approximately 3 ml of water and filtered through a
2-mm Acrodisc LC13 polyvinylidene fluoride (PVDF) syringe
filter (Pall Gelman Sciences, Inc., Ann Arbor, MI, USA). The
filtrate was then left to recrystallize overnight on a watch glass.
Preparation of valine hydantoin from hemoglobin. The prepara-
tion of valine hydantoin from hemoglobin was based on the
method by Manning et al [45]. A 0.5 ml aliquot of red blood cells
was placed into a heavy walled 15 ml screw top test tube. To this
was added 5 ml of 2% (wt/vol) HCl in acetone (4°C). The mixture
was vortexed, centrifuged for three minutes at 3000 3 g and the
supernatant discarded. The pellet was washed three times with 5
ml of acetone to remove all the heme. The off-white pellet was
then washed with 5 ml of diethyl ether, centrifuged and heated in
warm water (ca. 45°C) until dry. The pellet was then suspended in
0.5 ml of 50% glacial acetic acid and 0.5 ml of concentrated HCl.
The tube was capped with a glass marble and the mixture heated
for one hour at 100°C in a dri-bath. The globin is subsequently
hydrolyzed. Carbamyl valine residues are released which then
spontaneously cyclizes to form valine hydantoins. The hydrolyzate
is cooled immediately in an ice bath. To this were added 0.8 ml of
10 N NaOH and 0.5 ml of saturated NaCl and the resulting
suspension mixed well. The pH at this point should be between 4
to 5 for optimal extraction. Then 100 ml of the internal standard,
100 mg/ml carbamyl norvaline, was added. The valine hydantoin
and carbamyl norvaline are then extracted by adding 5 ml of ethyl
acetate and vortexing for one minute. The ethyl acetate superna-
tant (4 ml) was transferred to a clean 10-ml borosilicate tube and
evaporated to dryness under a stream of air in a dri-bath (70°C).
The residue was then placed over NaOH pellets in a vacuum
dessicator overnight to remove the last traces of acid.
Measurement of valine hydantoin. The method of Kwan et al [21]
was adapted for the measurement of valine hydantoin. The mobile
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phase (6% acetonitrile) was prepared by first adjusting approxi-
mately 900 ml of Type I water (Milli-Q water system; Millipore
Corp., Milford, MA, USA) to pH 4.0 with 0.5 M acetic acid, adding
60 ml acetonitrile and diluting to a final volume of 1 liter. The
prepared extract was resuspended with 0.5 ml of the mobile phase,
filtered through a 2-mm PVDF filter syringe, and 50 ml were
autoinjected into a Shimadzu HPLC system (SCL-10A; Shimadzu
Corporation, Kyoto, Japan) fitted with a heated (45°C) Apex II
reversed-phase column (Jones Chromatography Ltd., Lakewood,
CO, USA). The absorbance was read at 210 nm. Each run
included two standards, 50 ml of valine hydantoin (10 mg/ml) and
50 ml of carbamyl norvaline (10 mg/ml).
Calculation of hemoglobin carbamylation. Carbamylated hemo-
globin, expressed as mg valine hydantoin/g hemoglobin (mg VH/g
Hb) was calculated according to the following formula:
CHb 5 ~A 3 0.5 mg/B 3 B/C 3 20!/g Hb
where A is the peak height of valine hydantoin (VH) in the
sample, B is the peak height of the 50 ml (0.5 mg) CNVal (external
standard), and C is the peak height of CNVal in sample (internal
standard). The ratio 0.5 mg/B converts the peak height of the
sample VH to mg VH, since the absorbance of VH is the same as
CNVal at 210 nm. The ratio of B/C is a correction factor for loss
during extraction and the value 20 adjusts for the volume injected
(50 ml) compared to the total volume (1 ml) prepared from 0.5 ml
of washed red blood cells. The amount of Hb in the sample is
calculated by multiplying the concentration of Hb (g/liter) in the
sample by the sample volume processed (0.5 ml).
The within-run coefficient of variation for the standards was
1.7% for both VH and CNVal. Between-run coefficient of vari-
ances for the standards VH and CNVal were 2.7% and 3.6%,
respectively. Variation between samples was calculated from
three patient samples prepared in duplicate and run in the same
batch. The within-run difference was 10.2% for VH and 2.5% for
CNVal.
Calculation of dialysis dose (Kt/V). Dialysis dose (Kt/V), was
calculated using a preprogramed calculator (Fresenius-Brent,
Toronto, ON, Canada) incorporating the variable volume single-
pool model developed by Gotch and Sargent [46].
Statistical analysis
Simple correlation calculations were done by using Microcal
Origin (Microcal Software Inc., Northhampton, MA, USA). Mul-
tiple regression analyses were performed using SAS (SAS Insti-
tute Inc., Cary, NC, USA), and weighted correlation coefficients
were calculated using BMDP (BMDP Statistical Software Inc.,
Los Angelas, CA, USA).
RESULTS
Carbamylated hemoglobin and carbamylated protein in normal
individuals and hemodialyzed patients
Figure 1 shows the relationship between carbamylated hemo-
globin and carbamylated total protein in normal (N 5 9) and
uremic patients (N 5 13). The overall correlation of carbamylated
hemoglobin with carbamylated total protein was highly significant
(P , 0.0001) with a correlation of 0.87 (0.01). Individually,
however, the normal group shows no association between CHb
and CTP values (r 5 0.07, P 5 0.85), and the uremic group shows
a fair association (r 5 0.61, P 5 0.026). Furthermore, a significant
difference was found between the normal and uremic groups with
carbamylated hemoglobin (P , 0.0001) and carbamylated total
protein (P , 0.0001). The mean value for carbamylated hemo-
globin in normal individuals was 53 (6 20) mg VH/g Hb, and in
uremic patients it was 157 (6 40) mg VH/g Hb. The mean value
for carbamylated total protein in normal individuals was 0.08 (6
0.009) A/mg protein, and in uremic patients it was 0.117 (6 0.011)
A/mg protein.
The relationship between carbamylated hemoglobin and car-
bamylated total protein also shows that the y-intercept crosses at
0.069 (absorbance/mg protein). This is a very high y-intercept
considering that the highest y-value is only about twice that value.
This may suggest that carbamylated total protein can be detected
sooner than carbamylated hemoglobin.
Longitudinal study: Correlation with uremic markers
The results of the longitudinal study comparing urea (pre-
and post-dialysis), Kt/V, carbamylated protein and carbamy-
lated hemoglobin in seven patients are shown in Figure 2.
There did not appear to be any clear relationships, or discern-
able patterns between any sets of curves that were consistent
among all patients.
Because of the very different half-lives of carbamylated protein
(3 weeks) and carbamylated hemoglobin (2 months), correlations
done at single times are of little value in assessing the relative
clinical utility of the two assays. Furthermore, it is difficult to
compare parameters that have different measurement scales. To
accommodate these obstacles another approach was taken to
analyze the data. The data were recalculated in terms of relative
percent change over time, that is, the initial time interval was set
to 0% change and each subsequent value was expressed relative to
the previous value in the time series. The mean and SD were
calculated for each test using the mean relative percent value for
each patient. Kt/V values varied the least (6.3% 6 3.3%) over this
time period, whereas CHb varied nearly five times more (30.1% 6
20.2). Pre-dialysis urea and CTP values had similar relative
fluctuations (18.3% 6 13.4% and 14.9% 6 7.5%, respectively),
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Fig. 1. Correlation between carbamylated plasma protein (CTP) and
carbamylated hemoglobin (CHb) in normal and uremic subjects. Rela-
tionship between carbamylated hemoglobin and carbamylated total pro-
tein in 9 normal (v) and 13 uremic (f) patients. The regression line was
y 5 2.9E24x 1 0.069 (r 5 0.87, SD 5 0.01, P , 0.0001). Duplicate
determinations were done for each sample.
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Fig. 2. Serial measurements of uremic markers
in hemodialyzed patients. A six-month
longitudinal study of traditional dialysis
markers, urea and Kt/V, with time-averaged
urea markers, carbamylated hemoglobin (CHb)
and carbamylated protein (CTP), in seven
thrice weekly hemodialyzed patients. Complete
data were unavailable for patients 5 and 7.
Patients 3 and 6 were diabetic. Symbols are:
() pre-urea; () post urea; (z z z C z z z) CHb,mg
VH/g Hb; (–n–) Kt/V, (z z z c z z z) CTP, A/mg
protein.
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between those of Kt/V and carbamylated hemoglobin values. This
indicates that CHb is a more sensitive in monitoring urea fluctu-
ations than either pre-dialysis urea, CTP, or the dialysis dose,
Kt/V.
Correlation calculations (using the relative % change data) did
not seem to reveal much more in terms of relationships than did
the visual observations of the initial data. No correlations between
any two tests were seen in most cases. Furthermore, the correla-
tions that did exist between any two tests were mixed, positive or
negative, and in very few cases were these correlations significant
(P , 0.05). The reason for these apparent ambiguities could be
due to the nature of the tests, that is, they do not measure the
same thing at the same time, or the lack of a larger sample size
(frequency of sampling and number of patients).
Correlations between pre-dialysis urea and CHb, and pre-
dialysis urea and CTP on the data sets (N 5 7) were done for each
time period (N 5 6). There was a much higher association
between pre-dialysis urea and CHb (r 5 0.97, 0.86, 0.71, 0.52, 0.51,
0.40) than with pre-dialysis urea and CTP (r 5 0.48, 0.77, 20.11,
0.66, 0.26, 0.08).
To achieve greater statistical power, multiple regression analy-
sis was done to statistically answer the question as to whether
there is a relationship between any two tests within a patient. The
overall correlation coefficient was obtained by removing the
variation due to individual subjects [47]. No significant correlation
was found with any combination of tests, which is probably a
reflection of the variation in the correlations of the individual
patients, that is, regression to the mean.
Furthermore, the data were also looked at in terms of between
subject correlation. That is, to answer the question whether on
average do patients with high (or low) values for test A also tend
to have high (or low) values for test B. The weighted correlation
coefficients were determined between various tests using the
subject means. The significance of the correlation was based on
the number of subjects (N 5 7) and not the number of data pairs
(N 5 40) because of the repeated observations per subject [48].
Significant correlations (at a 5 0.05, r 5 0.6786) were found
between CHb versus CTP (P 5 0.707) and CHb versus pre-dialysis
urea (P 5 0.671). The correlation between CTP versus pre-dialysis
urea was almost significant (P 5 0.534), and there was a very poor
correlation between Kt/V versus pre-dialysis urea (P 5 0.278).
The other comparisons done were between Kt/V versus CTP or
CHb (P 5 20.327 and 20.387, respectively).
Laboratory tests for the seven hemodialyzed patients showed
that all had low hemoglobin concentrations and low hematocrits.
Albumin values were within the reference interval and pre-dialysis
urea values were above the reference interval. Post-dialysis urea
values were all lower than pre-dialysis urea values and in some
patients within the reference range. Creatinine concentrations
were all well above the reference interval before dialysis and
decreased after dialysis, but remained above the reference inter-
val. Glucose was elevated only in the two diabetic patients. Values
for potassium, sodium, chloride, carbon dioxide, glucose, calcium
(total and ionized), phosphate, alkaline phosphatase, g-glutamyl
transferase, and aspartate aminotransferase were in the reference
range for most patients. No relationships were evident in cases
where there were elevated levels of an analyte when compared to
CHb, CTP or Kt/V values.
DISCUSSION
Carbamylated hemoglobin and carbamylated plasma protein in
normal individuals and hemodialyzed patients
The correlation between carbamylated hemoglobin and car-
bamylated total protein concentrations in normal individuals and
uremic subjects (Fig. 1) showed a high correlation (r 5 0.87).
Furthermore, the y-intercept showed a bias in favor of carbamy-
lated total protein. Similarly, in glycation studies the bias favors
fructosamine and corroborates other studies that show fruc-
tosamine as a shorter term indicator of glycemic control com-
pared to glycated hemoglobin [49].
Since assay methodology could also influence this bias, a
general idea for how much carbamylation (number of carbamyl
groups independent of site or rate of attachment) occurs on
albumin versus hemoglobin was obtained by interpolating data
from two representative studies [14, 21]. The amount of carbamy-
lation was assessed by comparing homocitrulline residues for
albumin and carbamyl valine residues for hemoglobin. This
comparison (molar ratio) showed that there was fivefold more
carbamyl groups on albumin [0.08 (0.06 to 0.12)] as compared
with hemoglobin (0.016 6 0.005) in normal individuals. Similarly,
there were also more carbamyl groups on albumin [0.027 (0.02 to
0.033)] than on hemoglobin (0.066 6 0.035) in patients with renal
failure (4-fold). Therefore, the potential for carbamylation is
greatest for plasma proteins where the concentration of urea and
cyanate are the highest.
Longitudinal study
This is the first longitudinal study that has looked at the changes
in carbamylated hemoglobin and carbamylated protein in hemo-
dialyzed patients. Parameters of dialysis dose (Kt/V), pre- and
post-dialysis urea, CHb and CTP for all seven patients were
measured and plotted with respect to the time interval (1 month).
Visual observation of these parameters did not show any strong
associations or trends (Fig. 2).
Although the correlations between pre-dialysis urea and CHb
were high for most time periods, they did not agree and few were
significant. The large range in correlation values (0.21, 0.51, 0.52,
0.71, 0.86, 0.98) suggests that there is no consistent relationship
between pre-dialysis urea concentration and CHb. This discrep-
ancy is probably due to the small sample size (N 5 7) or could also
be reflecting the large fluctuations in urea generated by dialysis.
Studies with larger sample sizes have shown inconsistent relation-
ships as well. Kwan et al [21] showed a correlation of 0.69 (N 5
20) in hemodialysis patients for pre-dialysis urea versus CHb.
However, Smith et al [22], using a similar method, showed a
correlation of only 0.44 (N 5 31) in hemodialysis patients. They
also found higher correlations in all other groups studied (control
r 5 0.55, N 5 20; chronic renal failure r 5 0.75, N 5 40;
continuous ambulatory peritoneal dialysis r 5 0.55, N 5 24;
transplant rejection r 5 0.87, N 5 14). Another study reported a
correlation of 0.84 in a combined group of normal and uremic
subjects [19].
The correlations between pre-dialysis urea and CTP among the
six time periods were very poor and widespread (20.38, 20.11,
0.07, 0.48, 0.66, 0.77). This variation could also be due to the same
factors as discussed above.
In general, the half-lives of carbamylated proteins (CTP) and
carbamylated hemoglobin (CHb) can be assumed to be similar to
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the half-lives of plasma proteins and hemoglobin (3 weeks and 2
months, respectively). Therefore, detecting a relationship be-
tween the CTP and CHb values when measurements are taken
only every 30 days is therefore difficult (Fig. 2). If time points had
been available weekly, the possibility of detecting a trend may
have increased. Also, since the patients studied were in good
control already (dialysis regime and diet), very little variation or
significant difference in any individual test was seen. Untreated
patients or patients on continuous ambulatory peritoneal dialysis
may have shown more suggestive results.
This longitudinal study showed no clear relationship between
pre-dialysis urea or Kt/V and CTP or CHb measurements.
Because hemodialysis patients are maintained on a fairly stable
dialysis regime, the utility of measuring carbamylated proteins
may be limited. However, they may be of value if concentrations
are above a predetermined cutoff value or a pattern emerges over
time. Kwan et al [23] reported that CHb concentrations , 175 mg
CVal/g Hb indicated adequate dialysis.
The interpretation of carbamylated hemoglobin concentration
can be complicated by the anemia in uremia, the shortened
life-span of erythrocytes, and transfusions that dilute the erythro-
cyte mass and the CHb concentration. Measurement of CTP,
however, would not be accompanied by these same problems. The
plasma protein content is relatively stable in patients with end-
stage renal disease, although lower than normal (nutritional
effect) [50].
Nonetheless, measurement of carbamylated hemoglobin may
reflect a therapeutic time interval that would be appropriate in the
clinical management of the uremic outpatient. Carbamylated
protein concentration, an index of integrated urea levels over the
preceding two weeks, may reflect adequacy of dialysis over too
short a time interval to be of much practical use in and outpatient
setting. However, in cases of acute renal failure the estimation of
carbamylated protein may be more appropriate than carbamy-
lated hemoglobin [25].
In summary, to our knowledge this study has for the first time
shown the relationship between CHb and CTP in hemodialyzed
patients. It has also found no correlation between these measure-
ments and Kt/V, the currently used, but poorly evaluated [39],
indicator of morbidity and mortality in the hemodialyzed patient.
Therefore, the data suggest that CHb and CTP are unique
indicators of uremia, and their potential value necessitates their
examination in a valid outcome study.
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APPENDIX
Abbreviations used in this article are: A/mg protein, absorbance/mg
protein; CHb, carbamylated hemoglobin; CHSA, carbamylated human
serum albumin; CNVal, N-carbamyl-DL-norvaline; CTP carbamylated
total protein; CVal, N-carbamyl-DL-valine; EDTA, ethylenediaminetet-
raacetic acid; Hb, hemoglobin; Kt/V, dialysis dose; PBS, phosphate
buffered saline; TAC, time averaged urea concentration; UKM, urea
kinetic modeling; VH, valine hydantoin.
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